You searched for: 04435

  1. MethoCult™ H4435 Enriched|04435

    MethoCult™ H4435 Enriched

    Methylcellulose-based medium with recombinant cytokines for human cells
    Catalog # 04435, 04445
    PIS SDS
  2. Identification of Colonies Derived from Human Hematopoietic Progenitors
    Wallchart

    Identification of Colonies Derived from Human Hematopoietic Progenitors

    Representative colony images and tips for identifying progenitor subtypes in CFU assays
  3. Manual

    Human Colony-Forming Unit (CFU) Assays Using MethoCult™

    Catalog #
    Product Name:
    00217
    Applications of the Hematopoietic Progenitor Assay Training Course
    00215
    Standardization of the Hematopoietic Progenitor Assay Training Course
    00602
    Human Bone Marrow Proficiency Testing Program
    00606
    Fresh Cord Blood Proficiency Testing Program
    00608
    Frozen Cord Blood Proficiency Testing Program
    04436
    MethoCult™ SF H4436
    04064
    Starter Kit for MethoCult™ H4034 Optimum
    04100
    MethoCult™ H4100
    04230
    MethoCult™ H4230
    04236
    MethoCult™ SF H4236
    04431
    MethoCult™ H4431
    04434
    MethoCult™ H4434 Classic
    04464
    Starter Kit for MethoCult™ H4434 Classic
    04531
    MethoCult™ H4531
    04535
    MethoCult™ H4535 Enriched Without EPO
    04536
    MethoCult™ SF H4536
    04564
    Starter Kit for MethoCult™ H4534 Classic Without EPO
    09300
    10% Bovine Serum Albumin in Iscove's MDM
    04035
    MethoCult™ H4035 Optimum Without EPO
    04330
    MethoCult™ H4330
    04034
    MethoCult™ H4034 Optimum
    04435
    MethoCult™ H4435 Enriched
    04534
    MethoCult™ H4534 Classic Without EPO
    04437
    MethoCult™ Express
    00215
    Standardization of the Hematopoietic Progenitor Assay Training Course
    00217
    Applications of the Hematopoietic Progenitor Assay Training Course
  4. Preparing and Plating Semi-Solid Medium
    1:52
    Video

    Preparing and Plating Semi-Solid Medium

    Publish Date: March 02, 2017 Views: 0
  5. MethoCult™ Media for Performing Hematopoietic Colony-Forming Unit (CFU) Assays
    Brochure

    MethoCult™ Media for Performing Hematopoietic Colony-Forming Unit (CFU) Assays

    Cell Culture Media and Supplements
    MethoCult
  6. Hematopoietic Stem and Progenitor Cells - Products for Your Research
    Brochure

    Hematopoietic Stem and Progenitor Cells - Products for Your Research

    Cell Culture Media and Supplements
    ErythroClear, MethoCult, MyeloCult, SmartDish, StemSpan, STEMvision
  7. CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells
    55:51
    Webinar

    CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells

    Publish Date: June 26, 2018 Views: 0
  8. Troubleshooting In Vitro Expansion of Leukemic Cells
    45:17
    Webinar

    Troubleshooting In Vitro Expansion of Leukemic Cells

    Publish Date: July 16, 2019 Views: 0
  9. Hematopoietic Stem and Progenitor Cells (HSPCs)
    Mini Review

    Hematopoietic Stem and Progenitor Cells (HSPCs): Isolation, Culture, and Assays

    Hematopoietic Stem and Progenitor Cells
  10. Safety Data Sheet (SDS)

    DX20860-SDS_2_0_0.pdf

    Catalog #
    Product Name:
    04435
    MethoCult™ H4435 Enriched
    04445
    MethoCult™ H4435 Enriched
  11. Product Information Sheet (PIS)

    29539-PIS_2_4_2.pdf

    Catalog #
    Lot
    Language
    Product Name:
    04435
    All
    English
    MethoCult™ H4435 Enriched
    04445
    All
    English
    MethoCult™ H4435 Enriched
  12. Product Information Sheet (PIS)

    29539-PIS_2_4_0.pdf

  13. Reference
    Coata G et al. (JAN 2001) Stem cells (Dayton, Ohio) 19 6 534--42

    Prenatal diagnosis of genetic abnormalities using fetal CD34+ stem cells in maternal circulation and evidence they do not affect diagnosis in later pregnancies.

    In the present study, we report a new method for enrichment and analysis of fetal CD34+ stem cells after culture in order to determine whether it is feasible for noninvasive prenatal diagnosis. We also determined whether fetal CD34+ stem cells persist in maternal blood after delivery and assessed whether they have an impact on noninvasive prenatal diagnosis of genetic abnormalities. Peripheral blood samples were obtained from 35 pregnant women, 13 non-pregnant women who had given birth to male offsprings, 12 women who had never been pregnant, and eight pregnant women with male fetuses. CD34+ stem cells were enriched and either cultured for prenatal diagnosis or analyzed with fluorescence in situ hybridization (FISH)/polymerase chain reaction (PCR) to determine peristance in maternal blood. Fetal/maternal cells can be isolated and grown in vitro" to provide enough cells for a more accurate fetal sex or aneuploid prediction than is provided by unenriched and uncultured CD34+ stem cells. The presence of fetal cells in maternal blood samples from mothers who had given birth to male offspring was found in 3 of 13 blood samples. PCR was positive for Y chromosome in one woman who had never been pregnant. Analysis of cultured CD34+ stem cells from mothers with Y PCR positivity did not detect any male cells in any samples. Even if PCR positivity is due to persistence of fetal stem cells from previous pregnancies� View Publication
    Catalog #:
    Product Name:
    04435
    MethoCult™ H4435 Enriched
  14. Reference
    Stier S et al. (AUG 2003) Blood 102 4 1260--6

    Ex vivo targeting of p21Cip1/Waf1 permits relative expansion of human hematopoietic stem cells.

    Relative quiescence is a defining characteristic of hematopoietic stem cells. Reasoning that inhibitory tone dominates control of stem cell cycling, we previously showed that mice engineered to be deficient in the cyclin-dependent kinase inhibitor, p21Cip1/Waf1 (p21), have an increased stem cell pool under homeostatic conditions. Since p21 was necessary to maintain stem cell quiescence and its absence sufficient to permit increased murine stem cell cycling, we tested whether reduction of p21 alone in human adult-derived stem cells could affect stem cell proliferation. We demonstrate here that interrupting p21 expression ex vivo resulted in expanded stem cell number and in vivo stem cell function compared with control, manipulated cells. Further, we demonstrate full multilineage reconstitution capability in cells where p21 expression was knocked down. Therefore, lifting the brake on cell proliferation by altering cell cycle checkpoints provides an alternative paradigm for increasing hematopoietic stem cell numbers. This approach may be useful for relative ex vivo human stem cell expansion. View Publication
    Catalog #:
    Product Name:
    05100
    MyeloCult™ H5100
    04435
    MethoCult™ H4435 Enriched
  15. Reference
    Kuhara M et al. (NOV 2004) Analytical chemistry 76 21 6207--13

    Magnetic cell separation using antibody binding with protein a expressed on bacterial magnetic particles.

    Bacterial magnetic particles (BacMPs) are efficient platforms of proteins for surface display systems. In this study, mononuclear cells from peripheral blood were separated using BacMPs expressing protein A on the BacMP membrane surface (protein A-BacMPs), which were complexed with the Fc fragment of anti-mouse IgG antibody. The procedure of positive selection involves incubation of mononuclear cells and mouse monoclonal antibodies against different cell surface antigens (CD8, CD14, CD19, CD20) prior to treatment with protein A-BacMP binding with rabbit anti-mouse IgG secondary antibodies. Flow cytometric analysis showed that approximately 97.5 +/- 1.7% of CD19(+) and CD20(+) cells were involved in the positive fraction after magnetic separation. The ratio of the negative cells in the negative fraction was approximately 97.6 +/-1.4%. This indicates that CD19(+) and CD20(+) cells can be efficiently separated from mononuclear cells. Stem cell marker (CD34) positive cells were also separated using protein A-BacMP binding with antibody. May-Grunwald Giemsa stain showed a high nuclear/cytoplasm ratio, which indicates a typical staining pattern of stem cells. The separated cells had the capability of colony formation as hematopoietic stem cells. Furthermore, the inhibitory effect of magnetic cell separation on CD14(+) cells was evaluated by measurement of cytokine in the culture supernatant by ELISA when the cells were cultured with or without lipopolysaccharide (LPS). The induction of IL1-beta, TNFalpha, and IL6 was observed in the presence of 1 ng/mL LPS in all fractions. On the other hand, in the absence of LPS, BacMPs had little immunopotentiation to CD14(+) cells as well as that of artificial magnetic particles, although TNFalpha and IL6 were slightly induced in the absence of LPS in the positive fraction. View Publication
    Catalog #:
    Product Name:
    04435
    MethoCult™ H4435 Enriched
  16. Reference
    Fang B et al. (APR 2005) Blood 105 7 2733--40

    Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics.

    Overwhelming evidence from leukemia research has shown that the clonal population of neoplastic cells exhibits marked heterogeneity with respect to proliferation and differentiation. There are rare stem cells within the leukemic population that possess extensive proliferation and self-renewal capacity not found in the majority of the leukemic cells. These leukemic stem cells are necessary and sufficient to maintain the leukemia. Interestingly, the BCR/ABL fusion gene, which is present in chronic myelogenous leukemia (CML), was also detected in the endothelial cells of patients with CML, suggesting that CML might originate from hemangioblastic progenitor cells that can give rise to both blood cells and endothelial cells. Here we isolated fetal liver kinase-1-positive (Flk1+) cells carrying the BCR/ABL fusion gene from the bone marrow of 17 Philadelphia chromosome-positive (Ph+) patients with CML and found that these cells could differentiate into malignant blood cells and phenotypically defined endothelial cells at the single-cell level. These findings provide direct evidence for the first time that rearrangement of the BCR/ABL gene might happen at or even before the level of hemangioblastic progenitor cells, thus resulting in detection of the BCR/ABL fusion gene in both blood and endothelial cells. View Publication
    Catalog #:
    Product Name:
    04435
    MethoCult™ H4435 Enriched
  17. Reference
    Neves H et al. (MAY 2006) Stem cells (Dayton, Ohio) 24 5 1328--37

    Effects of Delta1 and Jagged1 on early human hematopoiesis: correlation with expression of notch signaling-related genes in CD34+ cells.

    It has been shown that Notch signaling mediated by ligands of both Jagged and Delta families expands the hematopoietic stem cell compartment while blocking or delaying terminal myeloid differentiation. Here we show that Delta1- and Jagged1-expressing stromal cells have distinct effects on the clonogenic and differentiation capacities of human CD34(+) CD38(+) cells. Jagged1 increases the number of bipotent colony-forming unit-granulocyte macrophage (CFU-GM) and unipotent progenitors (CFU-granulocytes and CFU-macrophages), without quantitatively affecting terminal cell differentiation, whereas Delta1 reduces the number of CFU-GM and differentiated monocytic cells. Expression analysis of genes coding for Notch receptors, Notch targets, and Notch signaling modulators in supernatant CD34(+) cells arising upon contact with Jagged1 and Delta1 shows dynamic and differential gene expression profiles over time. At early time points, modest upregulation of Notch1, Notch3, and Hes1 was observed in Jagged1-CD34(+) cells, whereas those in contact with Delta1 strikingly upregulated Notch3 and Hes1. Later, myeloid progenitors with strong clonogenic potential emerging upon contact with Jagged1 upregulated Notch1 and Deltex and downregulated Notch signaling modulators, whereas T/NK progenitors originated by Delta1 strikingly upregulated Notch3 and Deltex and, to a lesser extent, Hes1, Lunatic Fringe, and Numb. Together, the data unravel previously unrecognized expression patterns of Notch signaling-related genes in CD34(+) CD38(+) cells as they develop in Jagged1- or Delta1-stromal cell environments, which appear to reflect sequential maturational stages of CD34(+) cells into distinct cell lineages. View Publication
    Catalog #:
    Product Name:
    04435
    MethoCult™ H4435 Enriched
  18. Reference
    Jamieson CHM et al. (APR 2006) Proceedings of the National Academy of Sciences of the United States of America 103 16 6224--9

    The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.

    Although a large proportion of patients with polycythemia vera (PV) harbor a valine-to-phenylalanine mutation at amino acid 617 (V617F) in the JAK2 signaling molecule, the stage of hematopoiesis at which the mutation arises is unknown. Here we isolated and characterized hematopoietic stem cells (HSC) and myeloid progenitors from 16 PV patient samples and 14 normal individuals, testing whether the JAK2 mutation could be found at the level of stem or progenitor cells and whether the JAK2 V617F-positive cells had altered differentiation potential. In all PV samples analyzed, there were increased numbers of cells with a HSC phenotype (CD34+CD38-CD90+Lin-) compared with normal samples. Hematopoietic progenitor assays demonstrated that the differentiation potential of PV was already skewed toward the erythroid lineage at the HSC level. The JAK2 V617F mutation was detectable within HSC and their progeny in PV. Moreover, the aberrant erythroid potential of PV HSC was potently inhibited with a JAK2 inhibitor, AG490. View Publication
    Catalog #:
    Product Name:
    04435
    MethoCult™ H4435 Enriched
  19. Reference
    Gazda HT et al. (SEP 2006) Stem cells (Dayton, Ohio) 24 9 2034--44

    Defective ribosomal protein gene expression alters transcription, translation, apoptosis, and oncogenic pathways in Diamond-Blackfan anemia.

    Diamond-Blackfan anemia (DBA) is a broad developmental disease characterized by anemia, bone marrow (BM) erythroblastopenia, and an increased incidence of malignancy. Mutations in ribosomal protein gene S19 (RPS19) are found in approximately 25% of DBA patients; however, the role of RPS19 in the pathogenesis of DBA remains unknown. Using global gene expression analysis, we compared highly purified multipotential, erythroid, and myeloid BM progenitors from RPS19 mutated and control individuals. We found several ribosomal protein genes downregulated in all DBA progenitors. Apoptosis genes, such as TNFRSF10B and FAS, transcriptional control genes, including the erythropoietic transcription factor MYB (encoding c-myb), and translational genes were greatly dysregulated, mostly in diseased erythroid cells. Cancer-related genes, including RAS family oncogenes and tumor suppressor genes, were significantly dysregulated in all diseased progenitors. In addition, our results provide evidence that RPS19 mutations lead to codownregulation of multiple ribosomal protein genes, as well as downregulation of genes involved in translation in DBA cells. In conclusion, the altered expression of cancer-related genes suggests a molecular basis for malignancy in DBA. Downregulation of c-myb expression, which causes complete failure of fetal liver erythropoiesis in knockout mice, suggests a link between RPS19 mutations and reduced erythropoiesis in DBA. View Publication
    Catalog #:
    Product Name:
    04435
    MethoCult™ H4435 Enriched
  20. Reference
    Choi K-D et al. (MAR 2009) Stem cells (Dayton, Ohio) 27 3 559--67

    Hematopoietic and endothelial differentiation of human induced pluripotent stem cells.

    Induced pluripotent stem cells (iPSCs) provide an unprecedented opportunity for modeling of human diseases in vitro, as well as for developing novel approaches for regenerative therapy based on immunologically compatible cells. In this study, we employed an OP9 differentiation system to characterize the hematopoietic and endothelial differentiation potential of seven human iPSC lines obtained from human fetal, neonatal, and adult fibroblasts through reprogramming with POU5F1, SOX2, NANOG, and LIN28 and compared it with the differentiation potential of five human embryonic stem cell lines (hESC, H1, H7, H9, H13, and H14). Similar to hESCs, all iPSCs generated CD34(+)CD43(+) hematopoietic progenitors and CD31(+)CD43(-) endothelial cells in coculture with OP9. When cultured in semisolid media in the presence of hematopoietic growth factors, iPSC-derived primitive blood cells formed all types of hematopoietic colonies, including GEMM colony-forming cells. Human induced pluripotent cells (hiPSCs)-derived CD43(+) cells could be separated into the following phenotypically defined subsets of primitive hematopoietic cells: CD43(+)CD235a(+)CD41a(+/-) (erythro-megakaryopoietic), lin(-)CD34(+)CD43(+)CD45(-) (multipotent), and lin(-)CD34(+)CD43(+)CD45(+) (myeloid-skewed) cells. Although we observed some variations in the efficiency of hematopoietic differentiation between different hiPSCs, the pattern of differentiation was very similar in all seven tested lines obtained through reprogramming of human fetal, neonatal, or adult fibroblasts with three or four genes. Although several issues remain to be resolved before iPSC-derived blood cells can be administered to humans for therapeutic purposes, patient-specific iPSCs can already be used for characterization of mechanisms of blood diseases and for identification of molecules that can correct affected genetic networks. View Publication
    Catalog #:
    Product Name:
    04435
    MethoCult™ H4435 Enriched
  21. Reference
    Larochelle A et al. (FEB 2011) Blood 117 5 1550--4

    Human and rhesus macaque hematopoietic stem cells cannot be purified based only on SLAM family markers.

    Various combinations of antibodies directed to cell surface markers have been used to isolate human and rhesus macaque hematopoietic stem cells (HSCs). These protocols result in poor enrichment or require multiple complex steps. Recently, a simple phenotype for HSCs based on cell surface markers from the signaling lymphocyte activation molecule (SLAM) family of receptors has been reported in the mouse. We examined the possibility of using the SLAM markers to facilitate the isolation of highly enriched populations of HSCs in humans and rhesus macaques. We isolated SLAM (CD150(+)CD48(-)) and non-SLAM (not CD150(+)CD48(-)) cells from human umbilical cord blood CD34(+) cells as well as from human and rhesus macaque mobilized peripheral blood CD34(+) cells and compared their ability to form colonies in vitro and reconstitute immune-deficient (nonobese diabetic/severe combined immunodeficiency/interleukin-2 γc receptor(null), NSG) mice. We found that the CD34(+) SLAM population contributed equally or less to colony formation in vitro and to long-term reconstitution in NSG mice compared with the CD34(+) non-SLAM population. Thus, SLAM family markers do not permit the same degree of HSC enrichment in humans and rhesus macaques as in mice. View Publication
    Catalog #:
    Product Name:
    04435
    MethoCult™ H4435 Enriched
  22. Reference
    M. V. J. Braham et al. (apr 2019) Advanced healthcare materials e1801444

    A Human Hematopoietic Niche Model Supporting Hematopoietic Stem and Progenitor Cells In Vitro.

    Niches in the bone marrow regulate hematopoietic stem and progenitor cell (HSPC) fate and behavior through cell-cell interactions and soluble factor secretion. The niche-HSPC crosstalk is a very complex process not completely elucidated yet. To aid further investigation of this crosstalk, a functional in vitro 3D model that closely represents the main supportive compartments of the bone marrow is developed. Different combinations of human stromal cells and hydrogels are tested for their potential to maintain CD34+ HSPCs. Cell viability, clonogenic hematopoietic potential, and surface marker expression are assessed over time. Optimal HSPC support is obtained in presence of adipogenic and osteogenic cells, together with progenitor derived endothelial cells. When cultured in a bioactive hydrogel, the supportive cells self-assemble into a hypoxic stromal network, stimulating CD34+ CD38+ cell formation, while maintaining the pool of CD34+ 38- HSPCs. HSPC clusters colocalize with the stromal networks, in close proximity to sinusoidal clusters of CD31+ endothelial cells. Importantly, the primary in vitro niche model supports HSPCs with no cytokine addition. Overall, the engineered primary 3D bone marrow environment provides an easy and reliable model to further investigate interactions between HSPCs and their endosteal and perivascular niches, in the context of normal hematopoiesis or blood-related diseases. View Publication
    Catalog #:
    Product Name:
    04435
    MethoCult™ H4435 Enriched
  23. Reference
    Kurita R et al. (SEP 2006) Stem cells (Dayton, Ohio) 24 9 2014--22

    Tal1/Scl gene transduction using a lentiviral vector stimulates highly efficient hematopoietic cell differentiation from common marmoset (Callithrix jacchus) embryonic stem cells.

    The development of embryonic stem cell (ESC) therapies requires the establishment of efficient methods to differentiate ESCs into specific cell lineages. Here, we report the in vitro differentiation of common marmoset (CM) (Callithrix jacchus) ESCs into hematopoietic cells after exogenous gene transfer using vesicular stomatitis virus-glycoprotein-pseudotyped lentiviral vectors. We transduced hematopoietic genes, including tal1/scl, gata1, gata2, hoxB4, and lhx2, into CM ESCs. By immunochemical and morphological analyses, we demonstrated that overexpression of tal1/scl, but not the remaining genes, dramatically increased hematopoiesis of CM ESCs, resulting in multiple blood-cell lineages. Furthermore, flow cytometric analysis demonstrated that CD34, a hematopoietic stem/progenitor cell marker, was highly expressed in tal1/scl-overexpressing embryoid body cells. Similar results were obtained from three independent CM ESC lines. These results suggest that transduction of exogenous tal1/scl cDNA into ESCs is a promising method to induce the efficient differentiation of CM ESCs into hematopoietic stem/progenitor cells. View Publication
    Catalog #:
    Product Name:
    03434
    MethoCult™ GF M3434
    04435
    MethoCult™ H4435 Enriched
  24. Reference
    Lim CK et al. (JAN 2008) Journal of hematology & oncology 1 19

    Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells.

    BACKGROUND: Excessive maturation of hematopoietic cells leads to a reduction of long-term proliferative capability during cord blood (CB) expansion. In this study, we report the effects of anit-CD52 (Alemtuzumab, Campath) on both short- and long-term ex vivo expansion of CB hematopoietic stem cells (HSC) by evaluating the potential role of Alemtuzumab in preserving the repopulating capability in CB HSC and nonlymphoid progenitors. METHODS: Ex vivo expansion experiments were carried out using freshly purified CB CD34(+)cells in StemSpantrade mark SFEM medium in the presence of stem cell factor, Flt3-Ligand and thrombopoietin at 50 ng/ml. Alemtuzumab (10 microg/ml) was used to deplete CD52(+) cells during the cultures. Flow cytometry was used to monitor CB HSC and their differentiation. Colony forming unit (CFU) assays and long term culture-initiating cell (LTC-IC) assays were performed on cells obtained from day 0 (before culture) and day 14 after cultures. Secondary cultures was performed using CD34(+) cells isolated at 35 days from primary cultures and further cultured in StemSpantrade mark SFEM medium for another 14 days to confirm the long term effect of alemtuzumab in liquid cultures. RESULTS: Compared to cytokines alone, addition of alemtuzumab resulted in a significant increase in total nucleated cells, absolute CD34(+) cells, myeloid and megakaryocytic progenitors, multi-lineage and myeloid CFU and LTC-IC. CONCLUSION: The results from current study suggested that the use of alemtuzumab for ex vivo expansion of CBHSC maybe advantageous. Our findings may improve current technologies for CBHSC expansion and increase the availability of CB units for transplantation. However, in vivo studies using animal models are likely needed in further studies to test the hematopoietic effects using such expanded CB products. View Publication
    Catalog #:
    Product Name:
    01701
    ALDEFLUOR™ Assay Buffer
    04435
    MethoCult™ H4435 Enriched